AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15182985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligaflex
Number of subjects: 14
Study 11043547 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation (RPMS) treatment of the left forearm
Number of subjects: 14
Study 11043547 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional cueing
Number of subjects: 14
Study 11043547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RPMS or verbal cueing)
Number of subjects: 14
Study 9432635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg q.d. for 2 or 4 weeks)
Number of subjects: 326
Study 9432635 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg q.d. for 2 or 4 weeks)
Number of subjects: 326
Study 8458295 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteducational follow-up intervention via telephone contact
Number of subjects: 27
Study 8458295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no posteducational follow-up)
Number of subjects: 27
Study 3885915 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone, 30 mg/kg, every six hours for 48 hours
Number of subjects: 81
Study 3885915 — intervention group
Group type: COMPARATOR
Intervention: mannitol placebo
Number of subjects: 81
Study 31785387 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) - four applications
Number of subjects: 17
Study 31785387 — intervention group
Group type: COMPARATOR
Intervention: Combination of metronidazole (MTZ) and amoxicillin (AMX) - 3 tablets each for 7 days
Number of subjects: 17
Study 29437170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil (15 mL)
Number of subjects: 42
Study 27920516 — intervention group
Group type: EXPERIMENTAL
Intervention: Care pathway (CP) for COPD
Number of subjects: 342
Study 27920516 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 342
Study 24683565 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading group (IL group)
Number of subjects: 104
Study 24683565 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading group (CL group)
Number of subjects: 104
Study 24683565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 22111353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume group (7 ml x kg(‐1) predicted body weight), n = 8
Number of subjects: 16
Study 22111353 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal volume group (10 ml x kg(‐1) predicted body weight), n = 8
Number of subjects: 16
Study 20084314 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT)
Number of subjects: 50
Study 20084314 — intervention group
Group type: COMPARATOR
Intervention: Jogging (JOGG)
Number of subjects: 50
Study 20084314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CWT and JOGG
Number of subjects: 50
Study 17393617 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with drugs (treatment group)
Number of subjects: 65
Study 17393617 — intervention group
Group type: COMPARATOR
Intervention: Drugs only (control group)
Number of subjects: 65
Study 15514511 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week hamstring-stretching program (5 days/week, 30 seconds hold, 3 repetitions)
Number of subjects: 43
Study 15514511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 43
Study 11472316 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo oligosaccharides (10 g daily)
Number of subjects: 244
Study 11472316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 11472316 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo oligosaccharides
Number of subjects: 244
Study 9935261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alatrofloxacin (200 or 300 mg/day) followed by oral trovafloxacin (200 mg/day)
Number of subjects: 1701
Study 9935261 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intravenous or oral prophylaxis with alatrofloxacin or trovafloxacin
Number of subjects: 1701
Study 9935261 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 1701
Study 8186345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mesalazine (5-aminosalicylic acid) 2.4 g/day
Number of subjects: 110
Study 8186345 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 110
Study 3364822 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 10 mg
Number of subjects: 80
Study 3364822 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine 1 mg
Number of subjects: 80
Study 554446 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (10 to 60 mg daily)
Number of subjects: 30
Study 554446 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (100 to 600 mg daily)
Number of subjects: 30
Study 554446 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug holidays
Number of subjects: 30
Study 29907076 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (Plan A)
Number of subjects: 49
Study 29907076 — intervention group
Group type: COMPARATOR
Intervention: Safe in the City (SITC) video
Number of subjects: 49
Study 27790821 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Surgery
Number of subjects: 26
Study 27790821 — intervention group
Group type: COMPARATOR
Intervention: Conventional Surgery
Number of subjects: 26
Study 26262996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual GSH
Number of subjects: 20
Study 26262996 — intervention group
Group type: COMPARATOR
Intervention: Oral GSH
Number of subjects: 20
Study 26262996 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC)
Number of subjects: 20
Study 23333293 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-IV-AUD symptoms (AUDS)
Number of subjects: 2039
Study 23333293 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDS report
Number of subjects: 2039
Study 23333293 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDS stability
Number of subjects: 2039
Study 23333293 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pattern of AUDS
Number of subjects: 2039
Study 23333293 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDS in this age group
Number of subjects: 2039
Study 21536207 — intervention group
Group type: EXPERIMENTAL
Intervention: MP+FM (miniplates + facemask)
Number of subjects: 45
Study 21536207 — intervention group
Group type: EXPERIMENTAL
Intervention: FM (facemask)
Number of subjects: 45
Study 21536207 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 18818130 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with cytokine-induced killer cells for 3 courses (CIK-I group)
Number of subjects: 127
Study 18818130 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with cytokine-induced killer cells for 6 courses (CIK-II group)
Number of subjects: 127
Study 18818130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative adjuvant therapy)
Number of subjects: 127
Study 18818130 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival among the three groups
Number of subjects: 127
Study 17334301 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation-assisted adenotonsillectomy (CAA)
Number of subjects: 46
Study 17334301 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection adenotonsillectomy (CDA)
Number of subjects: 46
Study 15121376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 2290
Study 15121376 — intervention group
Group type: EXPERIMENTAL
Intervention: I(125) brachytherapy
Number of subjects: 2290
Study 15121376 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 2290
Study 11461949 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose CsA (target trough level 300 ng/ml)
Number of subjects: 313
Study 11461949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CsA (target trough level 150 ng/ml)
Number of subjects: 313
Study 11461949 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose CsA
Number of subjects: 313
Study 11461949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CsA
Number of subjects: 313
Study 9916865 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure test
Number of subjects: 10
Study 9916865 — intervention group
Group type: COMPARATOR
Intervention: Insulin-tolerance test (ITT)
Number of subjects: 10
Study 7924881 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory based blood glucometer (ROMEO, Diva Medical Systems) used by group III (8 patients who bought the system)
Number of subjects: 24
Study 7924881 — intervention group
Group type: COMPARATOR
Intervention: Memory based blood glucometer (ROMEO, Diva Medical Systems) used by group I (8 patients who returned the system within one month)
Number of subjects: 24
Study 7924881 — intervention group
Group type: COMPARATOR
Intervention: Memory based blood glucometer (ROMEO, Diva Medical Systems) used by group II (8 patients who used the system as a loan)
Number of subjects: 24
Study 2855478 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (2 litres, 0.9% NaCl) over 60 min
Number of subjects: 7
Study 2855478 — intervention group
Group type: COMPARATOR
Intervention: Control (no saline infusion)
Number of subjects: 7
Study 30653692 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the Comprehensive Approach to Rehabilitation (CARe) methodology
Number of subjects: 14
Study 30653692 — intervention group
Group type: COMPARATOR
Intervention: Control teams
Number of subjects: 14
Study 28219329 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated ultrafiltration (1 hour after 4 hours of HD)
Number of subjects: 9
Study 28219329 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis with ultrafiltration
Number of subjects: 9
Study 28219329 — intervention group
Group type: COMPARATOR
Intervention: Blood-volume-monitoring based ultrafiltration
Number of subjects: 9
Study 25577189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance‐based Counter Attitudinal Therapy group treatment
Number of subjects: 72
Study 25577189 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 72
Study 23727190 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on pregabalin at a dosage of 600 mg/day
Number of subjects: 40
Study 23727190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21227624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) therapy
Number of subjects: 80
Study 21227624 — intervention group
Group type: COMPARATOR
Intervention: AA aggregation and PFA‐100 Epi
Number of subjects: 80
Study 21227624 — intervention group
Group type: COMPARATOR
Intervention: AA aggregation and ADP aggregation
Number of subjects: 80
Study 21227624 — intervention group
Group type: COMPARATOR
Intervention: ADP aggregation and PFA‐100 Epi
Number of subjects: 80
Study 18506053 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative statin therapy
Number of subjects: 31725
Study 17255839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin-enhanced formula (850 mg/L)
Number of subjects: 52
Study 17255839 — intervention group
Group type: COMPARATOR
Intervention: Regular formula (102 mg/L)
Number of subjects: 52
Study 15284262 — intervention group
Group type: EXPERIMENTAL
Intervention: C+P (cisplatin 50 mg/m2 plus paclitaxel 135 mg/m2)
Number of subjects: 264
Study 15284262 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (50 mg/m2)
Number of subjects: 264
Study 11401078 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with 18F-fluoro-2-deoxy-D-glucose (FDG-PET)
Number of subjects: 0
Study 9597213 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg ephedrine i.m.
Number of subjects: 40
Study 9597213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8180055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal catheter
Number of subjects: 40
Study 8180055 — intervention group
Group type: COMPARATOR
Intervention: Medium concentration facemask
Number of subjects: 40
Study 3595698 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 24
Study 3595698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 24
Study 3595698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29697274 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid (EPA) 2 g/day
Number of subjects: 64
Study 29697274 — intervention group
Group type: COMPARATOR
Intervention: Standard polymeric diet (Control)
Number of subjects: 64
Study 28279495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy (ISTDP)
Number of subjects: 341
Study 28279495 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 341
Study 26197768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemoradiotherapy
Number of subjects: 254
Study 26197768 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy or radiotherapy alone
Number of subjects: 254
Study 22222177 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (3 exercises at proximal, medium, and distal segments of the lower limbs)
Number of subjects: 68
Study 22222177 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham treatment with disconnected ultrasound equipment)
Number of subjects: 68
Study 21439960 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pegylated IFN-α2a (360 μg once per week or 180 μg twice per week) with ribavirin (1.0-1.2 or 1.2-1.6 g/d) for up to 72 weeks
Number of subjects: 83
Study 21439960 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pegylated IFN-α with ribavirin
Number of subjects: 83
Study 18505948 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 176
Study 18505948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 18505948 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 176
Study 18505948 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (intention-to-treat analysis)
Number of subjects: 176
Study 18505948 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (intention-to-treat analysis)
Number of subjects: 176
Study 16927381 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based behavioral treatment
Number of subjects: 82
Study 16927381 — intervention group
Group type: COMPARATOR
Intervention: Non-exposure-based behavioral treatment
Number of subjects: 82
Study 16927381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (core treatment)
Number of subjects: 82
Study 12689783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiparetic stroke patients
Number of subjects: 15
Study 12689783 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 11218551 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping styles (behavioural and emotional disengagement)
Number of subjects: 147
Study 11218551 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment styles (less secure and more anxious)
Number of subjects: 147
Study 11218551 — intervention group
Group type: EXPERIMENTAL
Intervention: Income level
Number of subjects: 147
Study 8808422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg/day by continuous infusion
Number of subjects: 11
Study 8808422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 400 mg/day by continuous infusion
Number of subjects: 11
Study 1400937 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-across technique with medium supplemented with 20% follicular fluid
Number of subjects: 124
Study 1400937 — intervention group
Group type: COMPARATOR
Intervention: Swim-up technique (control)
Number of subjects: 124
Study 3859981 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information (INFO)
Number of subjects: 150
Study 3859981 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration (DEMO)
Number of subjects: 150
Study 3859981 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 31077790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive telephone‐based smoking cessation counseling intervention incorporating lung cancer screening results
Number of subjects: 345
Study 31077790 — intervention group
Group type: COMPARATOR
Intervention: Usual care (information pamphlet)
Number of subjects: 345
Study 30268713 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-appropriate preparation for children undergoing radiotherapy
Number of subjects: 63
Study 30268713 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (regardless of group)
Number of subjects: 63
Study 30268713 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 63
Study 26621361 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNgamma (human recombinant interferon 1 b gamma, trade name IMUKIN) administered in 3 subcutaneous escalating doses (100, 150 and 200 mug) over 4 weeks
Number of subjects: 9
Study 26621361 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNgamma (human recombinant interferon 1 b gamma, trade name IMUKIN)
Number of subjects: 9
Study 25350474 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid treatment with an average of 144.5 ± 127.8 mg/d of MED, including 57.1% long-acting and 91.4% short-acting opioids.
Number of subjects: 35
Study 25350474 — intervention group
Group type: COMPARATOR
Intervention: Positive urine drug tests (UDT) for illicit drugs or unprescribed medications (N = 15).
Number of subjects: 35
Study 23242399 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise intervention
Number of subjects: 60
Study 23242399 — intervention group
Group type: COMPARATOR
Intervention: usual care (control group)
Number of subjects: 60
Study 21029891 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 199
Study 21029891 — intervention group
Group type: COMPARATOR
Intervention: Manual SICS
Number of subjects: 199
Study 18936571 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative glucose (POG) levels
Number of subjects: 995
Study 18936571 — intervention group
Group type: EXPERIMENTAL
Intervention: American Society of Anesthesia Classification (ASAC)
Number of subjects: 995
Study 18936571 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency status
Number of subjects: 995
Study 18936571 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative glucose levels between 110 to 200 mg/dL
Number of subjects: 995
Study 18936571 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative glucose levels greater than 200 mg/dL
Number of subjects: 995
Study 15890138 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 457
Study 15890138 — intervention group
Group type: COMPARATOR
Intervention: Stroke team
Number of subjects: 457
Study 15890138 — intervention group
Group type: COMPARATOR
Intervention: Domiciliary care
Number of subjects: 457
Study 15890138 — intervention group
Group type: COMPARATOR
Intervention: General wards (with stroke team support)
Number of subjects: 457
Study 12181183 — intervention group
Group type: EXPERIMENTAL
Intervention: Barostat bag
Number of subjects: 8
Study 10513787 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 10
Study 10513787 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 10
Study 10513787 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide-5-mononitrate
Number of subjects: 10
Study 8557016 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (30.4 ± 0.8 degrees C)
Number of subjects: 19
Study 8557016 — intervention group
Group type: COMPARATOR
Intervention: Normothermic control group
Number of subjects: 19
Study 1936476 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35
Study 1936476 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 35
Study 1936476 — intervention group
Group type: COMPARATOR
Intervention: Metformin and Glibenclamide
Number of subjects: 35
Study 1936476 — intervention group
Group type: COMPARATOR
Intervention: Metformin (long term therapy)
Number of subjects: 35
Study 6757983 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 77
Study 6757983 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 77
Study 31472044 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate solubilizing + salt-tolerant bacteria at 4 dS/m salinity level
Number of subjects: 2
Study 31472044 — intervention group
Group type: EXPERIMENTAL
Intervention: Siderophore producing + salt-tolerant bacteria at 8 dS/m
Number of subjects: 2
Study 31472044 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate solubilizing + salt-tolerant bacteria at 8 dS/m
Number of subjects: 2
Study 29179559 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (3 days/week, 55-60 min/session from gestational Weeks 9-11 until Weeks 38-39)
Number of subjects: 65
Study 29179559 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 65
Study 27503042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 24
Study 27503042 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 50 mg (active control)
Number of subjects: 24
Study 27503042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25204467 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sided questionnaire
Number of subjects: 4600
Study 25204467 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet option
Number of subjects: 4600
Study 25204467 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sided questionnaire + Internet option
Number of subjects: 4600
Study 25204467 — intervention group
Group type: COMPARATOR
Intervention: No intervention (reference group)
Number of subjects: 4600
Study 23259498 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-Social Transitional Care Management Program (HSTCMP)
Number of subjects: 0
Study 23259498 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19699071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (NC) - 500 mg berberine, 200 mg red yeast rice, 10 mg policosanols
Number of subjects: 50